Takeaways from Biogen CEO’s conversation with BioCentury; plus, where things stand among NK cell companies and introducing newco Paratus
By Jeff Cranmer, Executive Editor
March 7, 2023 1:23 AM UTC
On the latest episode of the BioCentury This Week podcast, BioCentury’s editors assess the challenges and opportunities facing Christopher Viehbacher as he begins to implement his vision for Biogen Inc. (NASDAQ:BIIB). Viehbacher discussed Biogen’s future last week in a Q&A with BioCentury.
The team also analyzes the state of play among NK cell therapy companies and discusses highlights from BioCentury’s Emerging Company Profile of Paratus Sciences Corp., a well-funded biotech being built around the idea that insights derived from the study of bat biology can be applied directly to human health and health security.
This week’s podcast is sponsored by Jeito Capital. For information on how to sponsor BioCentury This Week and/or The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
